Litcius/Paper detail

Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA

Jingyan Wang, Yinzhi Yi, Xiaomin Wan, Xiaohui Zeng, Peng Ye, Chongqing Tan

2022Advances in Therapy18 citationsDOI

Topics & Concepts

MedicineTrastuzumab emtansineTrastuzumabOncologyInternal medicineMetastatic breast cancerHazard ratioBreast cancerCancerConfidence intervalHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Treatment and Pharmacology
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA | Litcius